All Stories

  1. The postoperative occurrence or worsening of diabetes mellitus may increase the risk of recurrence in resected pancreatic neuroendocrine tumors
  2. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
  3. High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRIL–ARF Bidirectional Promoter
  4. Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor
  5. Comparison of temozolomide-capecitabine to 5-fluorouracile-dacarbazine in 247 patients with advanced digestive neuroendocrine tumors using propensity score analyses
  6. Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset
  7. Inter- and intra-tumoral heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma
  9. La caractérisation moléculaire définit plusieurs sous-types d’adénocarcinome canalaire du pancréas
  10. Contribution of virtual biopsy to the screening of microvascular invasion in hepatocellular carcinoma: A pilot study
  11. 18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation
  12. Tumor Heterogeneity in Pancreatic Adenocarcinoma
  13. The Largest European Single-Center Experience: 300 Laparoscopic Pancreatic Resections
  14. 5-Fluorouracil biomarkers in pancreatic neuroendocrine tumours
  15. PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker
  16. Surgical Ampullectomy with Complete Resection of the Common Bile Duct: a New Procedure for Radical Resection of Non-invasive Ampulloma with Biliary Extension
  17. Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms
  18. Investigation at the micrometer scale of pancreatic calcifications in chronic pancreatitis by μFTIR spectroscopy and field emission scanning electron microscopy
  19. Stage-dependent fate of Plasmodium falciparum-infected red blood cells in the spleen and sickle-cell trait-related protection against malaria
  20. Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging
  21. Pancreatic ductal adenocarcinoma inBRCA2mutation carriers: Table 1
  22. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors
  23. Accuracy of 2012 International Consensus Guidelines for the prediction of malignancy of branch-duct intraductal papillary mucinous neoplasms of the pancreas
  24. Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma
  25. Well differentiated pancreatic neuroendocrine tumors (WDPNET) G3: Does the Ki67 really do it all?
  26. Metabolic state may define and predict resistance to mTOR-targeting therapies in pancreatic neuroendocrine tumors
  27. Distal intramural and tumor spread in the mesorectum after neoadjuvant radiochemotherapy in rectal cancer: about 124 consecutive patients
  28. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution
  29. State of the art and future directions of pancreatic ductal adenocarcinoma therapy
  30. Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma
  31. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors
  32. Parenchyma-sparing pancreatectomies for pancreatic neuroendocrine tumors
  33. Abstract 580: hENT1 testing in pancreatic ductal adenocarcinoma: Are we ready yet? A comparative analysis of the murine and the rabbit antibodies
  34. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place
  35. Gly388Arg FGFR4 polymorphism is not predictive of everolimus efficacy in well-differentiated digestive neuroendocrine tumors
  36. Comparative analysis between Sendai guidelines and the European experts consensus statement on BD-IPMN of the pancreas
  37. Decreased pS6 expression under MEK inhibitor (MEKi) correlates with response to MEKi alone or combined with PI3Ki-mTOR inhibitor (PI3Ki-mTORi) in pancreatic adenocarcinoma (PAC) in vitro and ex vivo models
  38. Neoadjuvant gemcitabine-oxaliplatin (GemOx) combination followed by chemoradiotherapy (CRT) in borderline pancreatic adenocarcinoma (BPC): A promising management
  39. Metachronous Hormonal Syndromes in Patients With Pancreatic Neuroendocrine Tumors
  40. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis
  41. Tu1942 hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready yet? A Comparative Analysis of the Murine and the Rabbit Antibodies
  42. Tu1918 Correlation Between the 18F-FDG Uptake Assessed by PET/CT and Pathological Data in Well-Differentiated Digestive Neuroendocrine Tumors
  43. 665 Contrast Harmonic Endoscopic Ultrasonography Is Able to Predict Aggressivity in Pancreatic Neuroendocrine Tumors
  44. Targeting the TGFβ pathway for cancer therapy
  45. Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma
  46. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies
  47. Experimental evidence for IS1294b-mediated transposition of the blaCMY-2 cephalosporinase gene in Enterobacteriaceae
  48. Lessons From McCune-Albright Syndrome–Associated Intraductal Papillary Mucinous Neoplasms
  49. CT and MR imaging of multilocular acinar cell cystadenoma: comparison with branch duct intraductal papillary mucinous neoplasia (IPMNs)
  50. Long-term outcome of pancreatic neuroendocrine tumours (PNET) in von Hippel-Lindau (VHL) compared to sporadic PNET : implications for management
  51. Evaluation of tumor response to targeted therapies in precision-cut slices of human pancreatic neuroendocrine tumors
  52. O6-methylguanine DNA methyltransferase (MGMT) expression and Ki67 index predict response to temozolomide in patients with well differentiated pancreatic neuroendocrine tumors (WDPNET)
  53. c-MET as a prognostic biomarker and therapeutic target in patients with poor prognostic pancreatic adenocarcinoma following surgical resection
  54. 327 O6-Methylguanine DNA Methyltransferase (MGMT) Expression and Ki67 Index Predict Response to Temozolomide in Patients With Well Differentiated Pancreatic Neuroendocrine Tumors (WDPNET)
  55. Reappraisal of Central Pancreatectomy
  56. MEK in cancer and cancer therapy
  57. Hepatobiliary and Pancreatic Neoplasms in Patients With McCune-Albright Syndrome
  58. Survival time estimation using Injury Severity Score (ISS) in homicide cases
  59. Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors
  60. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours
  61. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma
  62. Stromal expression of SPARC in pancreatic adenocarcinoma
  63. Tu1239 Postoperative Recurrence in Patients Operated on for Benign Intraductal Papillary Mucinous Neoplasms (IPMN)
  64. Mo1404 Solid Pancreatic Tumors in Young Patients (< 40 Years Old): What Is Your Diagnosis ?
  65. Postoperative recurrence in patients operated on for benign intraductal papillary mucinous neoplasms (IPMN)
  66. Master 2 (recherche). Tout ce que vous avez toujours voulu savoir sans jamais oser le demander !
  67. Les carcinomes des glandes salivaires : description histologique des principaux sous-types histologiques
  68. Homicidal Deaths in the Western Suburbs of Paris
  69. Methylguanine DNA methyl transferase (MGMT) expression predicts response to temozolomide (TMZ) in patients with digestive neuroendocrine tumors (NETs)
  70. Radiographic Examination Using an X-ray Tunnel (Passagix) Before a Forensic Autopsy
  71. Rôle de l’angiogenèse et rationnel d’utilisation des thérapies ciblées dans les tumeurs endocrines digestives
  72. Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors
  73. Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas
  74. Carcinome épidermoïde des voies aérodigestives supérieures : quoi de neuf en 2009
  75. Use of Reverse Genetics to Enhance the Oncolytic Properties of Newcastle Disease Virus
  76. Protection against Respiratory Syncytial Virus by a Recombinant Newcastle Disease Virus Vector
  77. Inhibition of Beta Interferon Induction by Severe Acute Respiratory Syndrome Coronavirus Suggests a Two-Step Model for Activation of Interferon Regulatory Factor 3
  78. An Unconventional NLS is Critical for the Nuclear Import of the Influenza A Virus Nucleoprotein and Ribonucleoprotein
  79. Mapping of the RNA promoter of Newcastle disease virus
  80. Induction of Cellular Immune Responses to Simian Immunodeficiency Virus Gag by Two Recombinant Negative-Strand RNA Virus Vectors
  81. Newcastle Disease Virus V Protein Is a Determinant of Host Range Restriction
  82. Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses
  83. Newcastle Disease Virus (NDV)-Based Assay Demonstrates Interferon-Antagonist Activity for the NDV V Protein and the Nipah Virus V, W, and C Proteins
  84. Recombinant Newcastle Disease Virus as a Vaccine Vector